188 related articles for article (PubMed ID: 25056974)
1. Drug treatment of macular oedema secondary to central retinal vein occlusion: a network meta-analysis.
Ford JA; Shyangdan D; Uthman OA; Lois N; Waugh N
BMJ Open; 2014 Jul; 4(7):e005292. PubMed ID: 25056974
[TBL] [Abstract][Full Text] [Related]
2. Treatments for macular oedema following central retinal vein occlusion: systematic review.
Ford JA; Clar C; Lois N; Barton S; Thomas S; Court R; Shyangdan D; Waugh N
BMJ Open; 2014 Feb; 4(2):e004120. PubMed ID: 24513867
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the efficacy and safety of drug therapies for macular edema secondary to central retinal vein occlusion.
Qian T; Zhao M; Wan Y; Li M; Xu X
BMJ Open; 2018 Dec; 8(12):e022700. PubMed ID: 30593547
[TBL] [Abstract][Full Text] [Related]
4. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
Mitry D; Bunce C; Charteris D
Cochrane Database Syst Rev; 2013 Jan; (1):CD009510. PubMed ID: 23440840
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy and safety of approved treatments for macular oedema secondary to branch retinal vein occlusion: a network meta-analysis.
Regnier SA; Larsen M; Bezlyak V; Allen F
BMJ Open; 2015 Jun; 5(6):e007527. PubMed ID: 26048209
[TBL] [Abstract][Full Text] [Related]
6. Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab.
Spooner K; Fraser-Bell S; Hong T; Chang A
Clin Exp Ophthalmol; 2020 Jan; 48(1):53-60. PubMed ID: 31498950
[TBL] [Abstract][Full Text] [Related]
7. Antivascular endothelial growth factors in the treatment of macular oedema secondary to central retinal vein occlusion: a meta-analysis.
Zhou S; Gao J; Xu X
Clin Exp Ophthalmol; 2014; 42(7):637-49. PubMed ID: 24330277
[TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy of bevacizumab, ranibizumab, and aflibercept for treatment of macular edema secondary to retinal vein occlusion: a systematic review and network meta-analysis.
Sangroongruangsri S; Ratanapakorn T; Wu O; Anothaisintawee T; Chaikledkaew U
Expert Rev Clin Pharmacol; 2018 Sep; 11(9):903-916. PubMed ID: 30071180
[TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness and harms of intravitreal antivascular endothelial growth factor agents for three retinal conditions: a systematic review and meta-analysis.
Low A; Faridi A; Bhavsar KV; Cockerham GC; Freeman M; Fu R; Paynter R; Kondo K; Kansagara D
Br J Ophthalmol; 2019 Apr; 103(4):442-451. PubMed ID: 30409915
[TBL] [Abstract][Full Text] [Related]
10. Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis.
Pham B; Thomas SM; Lillie E; Lee T; Hamid J; Richter T; Janoudi G; Agarwal A; Sharpe JP; Scott A; Warren R; Brahmbhatt R; Macdonald E; Straus SE; Tricco AC
BMJ Open; 2019 May; 9(5):e022031. PubMed ID: 31142516
[TBL] [Abstract][Full Text] [Related]
11. Current Outcomes of Anti-VEGF Therapy in the Treatment of Macular Oedema Secondary to Branch Retinal Vein Occlusions: A Meta-Analysis.
Spooner K; Hong T; Fraser-Bell S; Chang AA
Ophthalmologica; 2019; 242(3):163-177. PubMed ID: 31158837
[TBL] [Abstract][Full Text] [Related]
12. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema.
Virgili G; Parravano M; Menchini F; Brunetti M
Cochrane Database Syst Rev; 2012 Dec; 12():CD007419. PubMed ID: 23235642
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of switching treatment to aflibercept in patients with macular oedema secondary to central retinal vein occlusion refractory to ranibizumab.
Konidaris V; Al-Hubeshy Z; Tsaousis KT; Gorgoli K; Banerjee S; Empeslidis T
Int Ophthalmol; 2018 Feb; 38(1):207-213. PubMed ID: 28405787
[TBL] [Abstract][Full Text] [Related]
14. A meta-analysis of patients with treatment-resistant macular oedema secondary to retinal vein occlusions following switching to aflibercept.
Spooner K; Hong T; Bahrami B; Chang A
Acta Ophthalmol; 2019 Feb; 97(1):15-23. PubMed ID: 30251325
[TBL] [Abstract][Full Text] [Related]
15. Response to aflibercept as secondary therapy in patients with persistent retinal edema due to central retinal vein occlusion initially treated with bevacizumab or ranibizumab.
Eadie JA; Ip MS; Kulkarni AD
Retina; 2014 Dec; 34(12):2439-43. PubMed ID: 24999721
[TBL] [Abstract][Full Text] [Related]
16. EFFICACY AND FREQUENCY OF INTRAVITREAL AFLIBERCEPT VERSUS BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION.
Lotfy A; Solaiman KAM; Abdelrahman A; Samir A
Retina; 2018 Sep; 38(9):1795-1800. PubMed ID: 28767552
[TBL] [Abstract][Full Text] [Related]
17. The short-term efficacy of intravitreal ranibizumab, aflibercept and dexamethasone implant in the treatment of macular edema due to non-ischemic central retinal vein occlusion.
Yucel OE; Birinci H; Sullu Y
Int Ophthalmol; 2019 Apr; 39(4):891-901. PubMed ID: 29550932
[TBL] [Abstract][Full Text] [Related]
18. Aflibercept for Previously Treated Macular Edema Associated with Central Retinal Vein Occlusions: 1-Year Results of the NEWTON Study.
Khurana RN; Chang LK; Bansal AS; Palmer JD; Wu C; Wieland MR
Ophthalmol Retina; 2018 Feb; 2(2):128-133. PubMed ID: 31047339
[TBL] [Abstract][Full Text] [Related]
19. Anti-vascular endothelial growth factor for diabetic macular oedema.
Virgili G; Parravano M; Menchini F; Evans JR
Cochrane Database Syst Rev; 2014 Oct; (10):CD007419. PubMed ID: 25342124
[TBL] [Abstract][Full Text] [Related]
20. Outcome of "treat and monitor" regimen of aflibercept and ranibizumab in macular edema secondary to non-ischemic branch retinal vein occlusion.
Pichi F; Elbarky AM; Elhamaky TR
Int Ophthalmol; 2019 Jan; 39(1):145-153. PubMed ID: 29274022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]